Furosemide News and Research

RSS

Furosemide is a diuretic (water pill), a type of anthranilic derivative and loop diuretic with antihypertensive effect. Furosemide blocks the Na-K-Cl cotransporter (NKCC) in the luminal membrane of the thick ascending limb of the loop of Henle in the kidney, by binding to the Cl-binding site located in the cotransporter's transmembrane domain, thereby inhibiting reabsorption of sodium, chloride, potassium ions and water. This agent reduces plasma and extracellular fluid volume resulting in decreased blood pressure and cardiac output.

Hydroxychloroquine combined with azithromycin and abnormal heart rhythms in COVID-19 patients

A new study shows that the initially lauded combination of drugs against COVID-19 - Hydroxychloroquine and Chloroquine combined with azithromycin, could lead to abnormal and life-threatening heart rhythms. In patients hospitalized with the novel coronavirus infection or SARS CoV-2, this combination can lead to prolonged QT interval as can be detected on ECG.

3 May 2020

Study shows new treatment option for heart failure fluid overload

Higher doses of spironolactone, a diuretic (water pill), can prevent the need for dialysis in selected heart failure patients, a UT Health San Antonio study found.

2 Aug 2019

Reprieve Cardiovascular announces results of clinical trials in patients with acute heart failure

Reprieve Cardiovascular, a pioneering medical device company focused on improving outcomes for patients suffering from Acute Decompensated Heart Failure, today announced the results of two non-randomized, prospective clinical trials in patients hospitalized with Acute Heart Failure.

28 May 2019

Drug therapy for stable heart failure patients can be simplified by stopping diuretics

Drug therapy for patients with stable heart failure can be simplified by stopping diuretics, according to late-breaking results from the ReBIC-1 trial presented today at Heart Failure 2019, a scientific congress of the European Society of Cardiology.

27 May 2019

Harris Health System expert offers guidance to prevent drug-induced photosensitivity

Wanting a tan or simply enjoying the outdoors during the summer can expose skin to the effects of ultraviolet rays- a problem complicated for people taking certain medications, warns a Harris Health System expert.

10 Jul 2017

Scientists uncover genetic cause of rare pediatric progressive neuropathy

Researchers from the National Institutes of Health and their colleagues identified the genetic cause and a possible therapeutic target for a rare form of pediatric progressive neuropathy.

3 Aug 2016

Combining decongestion markers may guide HF hospital discharge

Patients hospitalised with acute heart failure who achieve good haemoconcentration in addition to a robust diuretic response are unlikely to be rehospitalised within the following 2 months, research suggests.

12 Jun 2016

Validus, Wood Creek announce acquisition of U.S. rights to several Sanofi US products

Validus Pharmaceuticals LLC, together with Wood Creek Capital Management, LLC ("Wood Creek"), announced today the acquisition of the U.S. rights to several well-known product lines from Sanofi US: Anzemet (dolasetron mesylate) Injection and Tablets, Claforan (cefotaxime) Injection/IM/IV, Demerol (meperidine hydrochloride) Tablets, Drisdol (ergocalciferol) Capsules and Oral Solution, Hiprex (methenamine hippurate) Tablets, Lasix (furosemide) Tablets, Norpramin (desipramine hydrochloride) Tablets and Trental (pentoxifylline) Tablets.

14 Dec 2015

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

United Therapeutics Corporation announced today that the European Commission (EC) has granted Marketing Authorisation for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT).

17 Aug 2015

Potassium supplements with loop diuretics increase survival rates of heart failure patients

Researchers from the Perelman School of Medicine at the University of Pennsylvania found that patients taking prescription potassium supplements together with loop diuretics for heart failure have better survival rates than patients taking diuretics without the potassium. Moreover, the degree of benefit increases with higher diuretic doses.

17 Jul 2014

Usability study for semi-disposable patch pump completed for subcutaneous furosemide therapy

Sensile Medical AG has completed the usability study for the semi-disposable patch pump that is developed for scPharmaceuticals LLC's novel subcutaneous furosemide therapy.

5 Mar 2014

Anticholinergic drugs might increase risk of cognitive impairment, death in older people

A side effect of many commonly used drugs appears to increase the risks of both cognitive impairment and death in older people, according to new research led by the University of East Anglia.

24 Jun 2011

Decision Resources: 52% of surveyed cardiologists identify furosemide as efficacious acute heart failure therapy

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the highest proportion of surveyed cardiologists identify furosemide as the most efficacious agent for the treatment of acute heart failure when compared to other available therapies.

1 Mar 2011

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.

12 Jan 2011

FDA approves Novartis' Amturnide for treatment of high blood pressure

Today Novartis announced that the US Food and Drug Administration (FDA) approved Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets for the treatment of high blood pressure. Amturnide combines the only approved direct renin inhibitor worldwide, Tekturna (aliskiren), with the widely used calcium channel blocker amlodipine and the diuretic hydrochlorothiazide (HCTZ).

23 Dec 2010

CRF announces additional featured trials to be presented at Transcatheter Cardiovascular Therapeutics 2010

The Cardiovascular Research Foundation has announced that in addition to the previously announced late breaking clinical trials and first reports, a series of additional featured trials will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium. These trials will focus on a wide range of significant topics in interventional cardiovascular medicine. TCT 2010 will take place September 21 - 25 in Washington, DC.

13 Aug 2010

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.

28 Jun 2010

POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVO

POZEN Inc., announced today the receipt of a $20 million milestone payment from AstraZeneca for the U.S. Food and Drug Administration approval of VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets on April 30th. POZEN will transfer ownership of the Investigational New Drug application and New Drug Application for VIMOVO to AstraZeneca over the next few weeks.

26 May 2010

VIMOVO delayed-release tablets receive FDA approval

AstraZeneca and POZEN Inc. today announced the U.S. Food and Drug Administration has approved VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.

3 May 2010

Parents lack understanding of causes, signs and symptoms of dehydration in children

Dehydration is a condition that can have a significant impact on children and, if left untreated, may lead to serious complications and hospitalization. A national survey of more than 800 parents with children between the ages of one month and 10 years found that three out of five parents reported needing to know more information about dehydration, such as when to see a physician, warning signs, and treatment, if their child became sick - pointing to a greater need for awareness and education around the condition and its treatment.

From Baxter International Inc. 8 Apr 2010